Analysis of Yeast Killer Toxin K1 Precursor Processing via Site-Directed Mutagenesis: Implications for Toxicity and Immunity

Stefanie Gier, Manfred J. Schmitt, Frank Breinig

Molecular and Cell Biology, Saarland University, Saarbrücken, Germany
Center of Human and Molecular Biology (ZHMB), Saarland University, Saarbrücken, Germany

ABSTRACT K1 represents a heterodimeric A/B toxin secreted by virus-infected Saccharomyces cerevisiae strains. In a two-staged receptor-mediated process, the ionophoric activity of K1 leads to an uncontrolled influx of protons, culminating in the breakdown of the cellular transmembrane potential of sensitive cells. K1 killer yeast necessitate not only an immunity mechanism saving the toxin-producing cell from its own toxin but, additionally, a molecular system inactivating the toxic α subunit within the secretory pathway. In this study, different derivatives of the K1 precursor were constructed to analyze the biological function of particular structural components and their influence on toxin activity as well as the formation of protective immunity. Our data implicate an inactivation of the α subunit during toxin maturation and provide the basis for an updated model of K1 maturation within the host cell's secretory pathway.

IMPORTANCE The killer phenotype in the baker’s yeast Saccharomyces cerevisiae relies on two double-stranded RNA viruses that are persistently present in the cytoplasm. As they carry the same receptor populations as sensitive cells, killer yeast cells need—in contrast to various bacterial toxin producers—a specialized immunity mechanism. The ionophoric killer toxin K1 leads to the formation of cation-specific pores in the plasma membrane of sensitive yeast cells. Based on the data generated in this study, we were able to update the current model of toxin processing, validating the temporary inactivation of the toxic α subunit during maturation in the secretory pathway of the killer yeast.

KEYWORDS K1, killer toxin, yeast viral toxin, Saccharomyces cerevisiae

The killer phenotype is a wide-spread phenomenon in various yeast strains and characterized by the secretion of proteinaceous compounds, so-called killer toxins, which are lethal to sensitive yeast strains. In the case of the baker’s yeast Saccharomyces cerevisiae, four virally encoded killer toxins (K1, K2, K28, and Klus) have been described based on their killing properties and the lack of cross-immunity (1). Killer yeast secreting these toxins are infected with two distinct double-stranded RNA viruses, M and L-A, persistently present in the cytoplasm of the host cell. Whereas the M virus encodes the respective toxin, L-A ensures the replication and maintenance of both mycoviruses by encoding the major capsid protein Gag and the RNA-dependent RNA polymerase Pol, which is expressed as a Gag-Pol fusion protein (2, 3). Primarily translated as precursor proteins (preprotoxin [pptox]), each killer toxin undergoes further maturation in the secretory pathway of its particular host cell. Mature K1 and K28 toxin molecules resemble classical A/B toxins consisting of one toxic α subunit and one β subunit, which is essential for target cell binding (3). Despite their different modes of action, the structural compositions as well as the processing of these killer toxin molecules are crucial for their toxic activity.
precursors are similar. Each preprotoxin consists of an N-terminal signal peptide (SP; preregion) critical for the import into the lumen of the endoplasmic reticulum (ER) followed by a preregion whose biological function has not yet been elucidated. Both major toxin subunits are separated by an additional γ component, which probably acts as an internal chaperone. After cleavage of the preregion and potential N-glycosylation of the γ subunit in the ER lumen, α and β are covalently linked via one single disulfide bond, and the toxin undergoes additional processing steps in the late Golgi compartment, involving the peptidases Kex2p and Kex1p (4). Eventually, the mature heterodimeric A/B toxin is packed into vesicles and secreted into the environment (5). Both killer toxins, K1 and K28, act in a receptor-mediated two-staged process, whereas the first step involves a rapid and energy-independent binding to the respective primary receptor in the cell wall (6, 7). In the case of K28, the heterodimeric toxin binds to its membrane receptor Erd2p, thereby parasitizing the retrograde transport machinery of the target cell. After translocation from the ER to the cytoplasm, the α subunit induces a cell cycle arrest in sensitive yeast (8, 9). In contrast, K1 toxin first binds to the β-1,6-glucan fraction within the yeast cell wall and is subsequently transferred to the plasma membrane level, where it interacts with its secondary receptor Kre1p (10, 11).

Early studies on K1 were able to demonstrate the strong hydrophobic character of the α subunit and the ability of the toxin to form pores into artificial membranes leading to a breakdown of the transmembrane gradient and death of sensitive cells (12, 13). The current model of toxin action allows both a direct insertion into the membrane as well as further interaction with one or more so far unknown primary effector protein(s) (10). Remarkably, killer toxin-producing yeast cells need a particular mechanism granting immunity against their own toxin. On a molecular level, this mechanism has only been elucidated for K28 and is essentially linked to the posttranslational import of the toxin precursor, which interacts with reinternalized mature toxin molecules in the cytosol, blocking their action (14). Based on the hydrophobicity of the K1 preregion, cotranslational ER import of the precursor molecule is proposed, which would exclude a comparable immunity mechanism; nevertheless, the preprotoxin and its import into the secretory pathway are critically involved in the formation of intrinsic immunity (15, 16). A reduction of the plasma membrane Kre1p population in K1 killer cells was suggested to confer immunity due to complexation of Kre1p and the K1 protoxin in the secretory pathway, leading to vacuolar degradation of this complex (17, 18). However, we were recently able to show that the plasma membrane receptor Kre1p is not involved in the immunity mechanism by intracellularly expressing different K1 derivatives in a Δkre1 null mutation background (15). Although a previously conducted comprehensive mutational analysis of the toxin precursor was able to show the importance of the γ subunit in K1 immunity, neither the exact mechanism of the toxic effect nor the intrinsic immunity have been completely elucidated to date (19). Based on existing hypotheses of K1 maturation, we constructed various K1 derivatives mutated in different toxin subunits to analyze the impact of these structural components in K1 biology. Via intracellular expression of these toxin constructs, we were able to further describe the biological function of specific steps in the K1 maturation process. Moreover, based on the generated data, we postulate a model suggesting the inactivation of the toxic α subunit in dependency of the preregion and γ region, thereby refining the current model of K1 precursor processing.

**RESULTS**

**Mutation of the K1 preregion.** The N-terminal preregion present in K1 and K28 precursors is necessary for ER import and, therefore, critical for further maturation of the particular toxin. We have previously shown that the posttranslational import of K28 pptox into the secretory pathway has direct implications for the immunity mechanism, saving the toxin-producing cell from its own reinternalized toxin (14). To extend the current understanding of the precursor’s ER import type, we systematically mutated the K1 preregion (amino acids [aa] 1 to 26) with the corresponding subunits of K28 (K1-K28-Pre) and the “mating type factor a” (MFA; K1-MFA-Pre), respectively, which are
both posttranslationally imported proteins (Fig. 1). In addition to the ER import sequence, we analyzed the consequences of different mutations of the K1 proregion (aa 27 to 44). This short but hydrophobic sequence, whose exact molecular function has not yet been elucidated, is removed in a Kex2p-dependent manner in late Golgi compartments of the killer yeast. However, the wild-type enzyme cleavage site (PR44-E45A) represents a moderate to weak recognition signal for the endopeptidase Kex2p, preferably acting at dibasic amino acid sequences. Thus, besides the complete substitution of the proregion with the corresponding K28 sequence alone (K1-K28-Pro) or in combination with the preregion [K1-K28(SS)], point mutations affecting the efficacy of the Kex2p cleavage site at the N terminus of the toxic subunit were introduced, creating either a strongly impaired (K1-R44A) or improved (K1-P43K) enzyme recognition site (Fig. 1). All derivatives were cloned into the multicopy vector pYES2.1 and transformed in the sensitive yeast strain BY4742. Subsequently, K1 toxicity, as well as the mediation of functional immunity, was analyzed via methylene blue agar (MBA) diffusion assay (see Fig. S1 and S2 in the supplemental material). Although the exchange of the K1 preregion with the respective sequence of K28 (K1-K28-Pre) or MFA (K1-MFA-Pre) slightly diminished immunity against extracellularly applied K1 toxin, no reduction in biological activity (i.e., secretion of biologically active toxin) was detected. Likewise, a wild-type phenotype regarding toxin secretion and immunity was observed after substitution of the K1 proregion by the corresponding K28 sequence (K1-K28-Pro). The combined replacement of the wild-type pre- and proregions by the K28-specific subunits, however, resulted in a loss of toxicity [K1-K28(SS)]. Concerning the point mutations altering the recognition site of Kex2p of the preregion, transformants expressing a K1 derivative with an enhanced enzyme recognition site showed a wild-type phenotype (K1-P43K). In clear contrast, the impairment of this cleavage site by substitution of arginine with the unipolar amino acid alanine resulted in a complete loss of toxicity, whereas respective transformants remained entirely immune against externally applied K1 toxin (K1-R44A) (Fig. 1).

Furthermore, we analyzed potential effects of the described mutations in the preregion on the pore-forming abilities of the toxin. Corresponding to previously described lethal constructs consisting only of the toxic subunit, truncated K1 derivatives containing the different preregions were obtained via PCR and expressed in the sensitive strain BY4742 (15). The potential impact of the mutations on the growth of the transformants (i.e., the suicidal phenotype) was analyzed via serial dilution assay.
The partial or full substitution of the K1 preproregion with either the corresponding sequence of killer toxin K28 [K1-\(\alpha\)(SS)-K28-Pre, K1-\(\alpha\)(SS)-K28-Pro, and K1-\(\alpha\)-K28(SS)] or MFA [K1-\(\alpha\)(SS)-MFA-Pre] thereby induced a wild-type growth defect in the respective transformants, indicating no effect of the mutations on the pore-forming ability of \(\alpha\). Interestingly, even under noninducing conditions (glucose), substantial growth defects were observed for these derivatives. Likewise, the enhancement of the Kex2p cleavage of the proregion [K1-\(\alpha\)(SS)-P43K] had no effect on the suicidal phenotype, whereas the transformants expressing lethal \(\alpha\) constructs with an impaired enzyme recognition site [K1-\(\alpha\)(SS)-R44A] were able to grow under inducing conditions (Fig. 2A). Potential interference of these mutated \(\alpha\) derivatives in the intrinsic immunity mechanism was further analyzed via serial dilution assay after cotransformation with the wild-type K1 preprotoxin (Fig. 2B). Regarding the \(\alpha\) constructs with fully or partially substituted preproregions [K1-\(\alpha\)(SS)-K28-Pre, K1-\(\alpha\)(SS)-K28-Pro, K1-\(\alpha\)-K28(SS), and K1-\(\alpha\)(SS)-MFA-Pre], a distinct loss in immunity was observed, which is generally granted by the precursor molecule in the secretory pathway, with no considerable difference.

![Figure 2A](msphere.asm.org) Intracellular expression of lethal constructs with mutated preproregions. Cells of the sensitive S. cerevisiae strain BY4742 were transformed with the indicated K1 \(\alpha\) derivatives, and logarithmic dilutions of \(10^6\) to \(10^1\) cells were spotted onto appropriate agar plates containing either glucose (noninducing conditions, left) or galactose (inducing conditions, right) as carbon source. Growth was documented after 3 days (30°C), and representative results are depicted (\(n = 15\)). (B) Cotransformation of mutated \(\alpha\) derivatives with wild-type toxin precursor. BY4742 cells were cotransformed with the indicated \(\alpha\) derivatives and the wild-type K1 precursors molecule (pYX242). Respective transformants were spotted in logarithmic dilutions (\(10^6\) to \(10^1\) cells) onto ura/leu/\((\text{d/o})\) agar plates (glucose: noninducing conditions, left; galactose: inducing conditions, right). Cell growth was documented after 3 days (30°C), and representative results were visualized (\(n = 15\)). K28-specific subunits are illustrated in black, MFA preregion is depicted in gray, and point mutations are marked by a black X.
Between the various lethal constructs. In contrast, no modification of the Kex2p recognition site [K1-\(\alpha\)(SS)-P\(_{43}\)K or K1-\(\alpha\)(SS)-R\(_{44}\)A] influenced the formation of functional immunity under inducing conditions, creating a wild-type phenotype (Fig. 2B).

**Mutation of the K1 \(\gamma\) subunit.** We also analyzed the potential effects of individual point mutations in the K1 \(\gamma\) subunit by either destroying the glycosylation sites (N\(_{181}\), N\(_{203}\), and N\(_{216}\)) or the intramolecular Kex2p recognition sequence (KR\(_{188}\)). Additionally, a complete substitution of \(\gamma\) with the corresponding K28 subunit was conducted (K1-K28). After the expression of the latter, no biological activity against intact sensitive cells was observed, but the respective transformants were still immune against externally applied K1 toxin. In contrast, cells expressing a K1 derivative with a nonfunctional intramolecular Kex2p cleavage site in \(\gamma\) (K1-K187L) secreted biologically active toxin but were not entirely immune when additional wild-type toxin was applied externally. Remarkably, mutation of the glycosylation sites had no effect on the biological activity of the respective secreted K1 derivatives nor on the ability to mediate functional immunity, and all constructs showed a wild-type phenotype (Fig. 3).

As previous studies already implied the importance of the \(\gamma\) subunit in the formation of immunity (19), we constructed \(\alpha\) derivatives that were either C-terminally extended by the complete \(\gamma\) sequence [K1-\(\alpha\)(SS)-P\(_{43}\)K or K1-\(\alpha\)(SS)-R\(_{44}\)A] or the N-terminal 39 amino acids of this subunit [K1-\(\alpha\)(SS) and K1-\(\alpha\)(SS)\(_{39}\)], which would remain after intramolecular cleavage by Kex2p. Intracellular expression of these constructs led to a diminution of the suicidal phenotype, showing the most significant impact of when the respective constructs were imported into the secretory pathway (Fig. 4A). This phenotype was also mirrored in cotransformational experiments with the wild-type toxin precursor and a truncated version (K1-tox lacking the preproregion) showing the potential of \(\alpha\)(SS) derivatives to grant immunity completely (see Fig. S3). The importance of the intramolecular Kex2p recognition site was further analyzed by subcloning of the point-mutated full-length toxin precursor (K1-K187L) into the vector pYX242. After coexpression with different wild-type \(\alpha\) constructs [\(\alpha\) and \(\alpha\)(SS)] in the multicopy vector pYE52.1 or a low-copy-number vector pRS316, respectively, cellular growth of the respective transformants was analyzed via serial dilution assay (Fig. 4B). Interestingly, and in sharp contrast to the wild-type precursor, no immunity was established by the mutated K1 precursor derivative independent of the cotransformed lethal construct.

### FIG 3
Effects of mutations within the K1 \(\gamma\) subunit. Depicted is the summary of the observed phenotypes regarding toxicity and immunity against extracellularly applied K1 toxin after expressing the indicated K1 derivatives in the sensitive strain BY4742. A wild-type phenotype (biological activity and functional immunity) is indicated as +, whereas no toxicity and loss of immunity are labeled −. Incomplete mediation of immunity (−) is defined by a reduction in growth but no distinct killing zone. Point mutations are indicated by a black X, and substitution with K28-specific sequences are illustrated in black. Images of representative results are depicted in Fig. S2B.

| GLYCOSYLATION MUTANTS | TOXICITY | IMMUNITY |
|------------------------|----------|----------|
| K1-K187L               | Pre Pro  | \(\alpha\) \(\gamma\) \(\beta\) | + | + |
| K1-K28                 | Pre Pro  | \(\alpha\) \(\gamma\) \(\beta\) | − | + |
| K1-N181Q               | Pre Pro  | \(\alpha\) \(\gamma\) \(\beta\) | + | + |
| K1-N203Q               | Pre Pro  | \(\alpha\) \(\gamma\) \(\beta\) | + | + |
| K1-N216Q               | Pre Pro  | \(\alpha\) \(\gamma\) \(\beta\) | + | + |
| K1-N181-203Q           | Pre Pro  | \(\alpha\) \(\gamma\) \(\beta\) | + | + |
| K1-N181-216Q           | Pre Pro  | \(\alpha\) \(\gamma\) \(\beta\) | + | + |
| K1-N203-216Q           | Pre Pro  | \(\alpha\) \(\gamma\) \(\beta\) | + | + |

| K1-N181-203-216Q       | Pre Pro  | \(\alpha\) \(\gamma\) \(\beta\) | + | + |

Between the various lethal constructs. In contrast, no modification of the Kex2p recognition site [K1-\(\alpha\)(SS)-P\(_{43}\)K or K1-\(\alpha\)(SS)-R\(_{44}\)A] influenced the formation of functional immunity under inducing conditions, creating a wild-type phenotype (Fig. 2B).

**Mutation of the K1 \(\gamma\) subunit.** We also analyzed the potential effects of individual point mutations in the K1 \(\gamma\) subunit by either destroying the glycosylation sites (N\(_{181}\), N\(_{203}\), and N\(_{216}\)) or the intramolecular Kex2p recognition sequence (KR\(_{188}\)). Additionally, a complete substitution of \(\gamma\) with the corresponding K28 subunit was conducted (K1-K28). After the expression of the latter, no biological activity against intact sensitive cells was observed, but the respective transformants were still immune against externally applied K1 toxin. In contrast, cells expressing a K1 derivative with a nonfunctional intramolecular Kex2p cleavage site in \(\gamma\) (K1-K187L) secreted biologically active toxin but were not entirely immune when additional wild-type toxin was applied externally. Remarkably, mutation of the glycosylation sites had no effect on the biological activity of the respective secreted K1 derivatives nor on the ability to mediate functional immunity, and all constructs showed a wild-type phenotype (Fig. 3 and S2).

As previous studies already implied the importance of the \(\gamma\) subunit in the formation of immunity (19), we constructed \(\alpha\) derivatives that were either C-terminally extended by the complete \(\gamma\) sequence [K1-\(\alpha\)(SS)-P\(_{43}\)K or K1-\(\alpha\)(SS)-R\(_{44}\)A] or the N-terminal 39 amino acids of this subunit [K1-\(\alpha\)(SS) and K1-\(\alpha\)(SS)\(_{39}\)], which would remain after intramolecular cleavage by Kex2p. Intracellular expression of these constructs led to a diminution of the suicidal phenotype, showing the most significant impact of when the respective constructs were imported into the secretory pathway (Fig. 4A). This phenotype was also mirrored in cotransformational experiments with the wild-type toxin precursor and a truncated version (K1-tox lacking the preproregion) showing the potential of \(\alpha\)(SS) derivatives to grant immunity completely (see Fig. S3). The importance of the intramolecular Kex2p recognition site was further analyzed by subcloning of the point-mutated full-length toxin precursor (K1-K187L) into the vector pYX242. After coexpression with different wild-type \(\alpha\) constructs [\(\alpha\) and \(\alpha\)(SS)] in the multicopy vector pYE52.1 or a low-copy-number vector pRS316, respectively, cellular growth of the respective transformants was analyzed via serial dilution assay (Fig. 4B). Interestingly, and in sharp contrast to the wild-type precursor, no immunity was established by the mutated K1 precursor derivative independent of the cotransformed lethal construct.
**DISCUSSION**

K1 is an ionophoric A/B toxin produced and secreted by virus-infected *Saccharomyces cerevisiae* strains killing sensitive yeast cells by destroying cytoplasmic membrane structures and functions. Similarly to mammalian precursor proteins such as insulin, K1 is initially translated as a preprotoxin with a distinct domain organization, undergoing various posttranslational modifications critical for its biological activity. Although many studies highlighted the importance of the toxin precursor’s import into the secretory pathway for the mediation of functional immunity in the toxin-producing cell, it is still unclear if the K1 preprotoxin is post- or cotranslationally transported into the ER (20, 21). Based on their fast growth, yeast and bacterial cells mostly prefer posttranslational import of peptides and proteins into the ER, as the number of Sec complexes/equivalents in the cell is limited. Cotranslational import only occurs for highly hydrophobic proteins that would otherwise accumulate in the cytoplasm (22, 23). Previous sequence analyses revealed several highly hydrophobic regions within the ionophoric toxin, predestining K1 for cotranslational ER import (24). Besides, the characterization of functional immunity against the killer toxin K28 illustrated that the underlying mechanism is tightly connected to the posttranslational ER import of the toxin precursor molecule (14). In an approach to analyze the ER transport of K1 preprotoxin *in vitro*, we substituted the preregion of the toxin with the corresponding sequence of K28 or MFA to ensure posttranslational import (14, 25). Although the respective transformants were able to

---

**FIG 4** (A) Intracellular expression of αγ derivatives. After transformation of *S. cerevisiae* with the indicated K1 αγ derivatives (with or without native K1 preregion [SS]), effects on cell growth were analyzed via serial dilution assay; 10^6 to 10^1 cells of the respective transformants were spotted onto glucose-containing (noninducing, left) or galactose-containing (inducing, right) agar plates. After 3 days at 30°C, growth was documented; depicted are representative results (n = 30). (B) Cotransformation of point-mutated toxin precursor with wild-type α constructs. Cotransformation of BY4742 cells was conducted using K1 α constructs with (αSS) or without the preregion (α) and a point mutated K1 pptox derivative with a nonfunctional Kex2p cleavage site (K1-K187L in pYX242). Lethal constructs were expressed either in the multicopy vector pYES2.1 or a low-copy-number vector pRS316. Transformants were spotted onto ura/leu d/o agar plates (glucose: noninducing, left; galactose: inducing, right). After incubation (3 days, 30°C), cell growth was documented, and representative results were visualized (n = 5).
secrete biologically active toxin, a reduction in cellular growth was observed after extracellular application of wild-type K1 toxin, indicating an impairment in the mediation of intrinsic immunity. Additional cotranslational experiments conducted using chimeric lethal constructs (derivatives lacking the γ and δ subunit) and the wild-type K1 preprotoxin resulted in complete growth inhibition of the transformants under inducing conditions. This observation further strengthened the hypothesis of cotranslational import of the K1 killer toxin while concurrently excluding an immunity mechanism similar to that for K28 (Fig. 5A).

After cleavage of the preregion by the signal peptidase complex in the ER, the newly generated N terminus consists of the so-called proregion, which is sometimes referred to as the δ subunit. Based on its highly hydrophobic properties, this short peptide is also proposed to be anchored within the luminal membrane during the maturation process until it is removed in a Kex2p-dependent manner in late Golgi compartments, generating the mature N terminus of α. During this process, the toxic α subunit is potentially kept inactivated by the membrane-bound proregion and parts of the γ subunit. Subsequently, the newly exposed dibasic arginines at the α C terminus are proteolytically removed by the carboxypeptidase Kex1p. The mature K1 heterodimer is transported to the plasma membrane and secreted into the extracellular medium. Previous studies additionally imply a transport of the γ sequence to the vacuole, which is important for the mediation of immunity. (Data from references 24 and 35 were used to create this figure.)
Interestingly, the latter completely diminished the toxic effect of α, which was also reproduced using lethal constructs. In addition to and in accordance with a previous study, we substituted the complete proregion with the corresponding sequence of K28 (14). The expression of these K1 derivatives (full-length toxin or α derivatives) had no influence on the secretion of biologically active toxin, functional immunity, or the development of the characteristic suicidal phenotype. However, as soon as both the pre- and the proregion of the killer toxin were substituted with the respective K28 subunits, a loss of toxicity and a diminution of immunity after extracellular application of wild-type K1 toxin were detected. In contrast to K1, the K28 proregion is even shorter and does not exhibit the same hydrophobicity profile but a comparable weak C-terminal Kex2p cleavage site. Based on our data, the K28 proregion does not seem to affect the general maturation process of K1 or the toxicity of the α subunit. However, the combined substitution of the whole preproregion led to an insufficient formation of immunity, implicating an inadequate number of precursor molecules in the secretory pathway to counteract the toxic effect, probably due to the posttranslation import of the mutated K1 preprotoxin. Taken together, we propose an involvement of the K1 proregion not only in the correct folding of the toxin heterodimer during its processing within the host cell but also in the inactivation of the toxic α subunit to the point of secretion.

In the first maturation steps occurring in the ER of the host cell, α and β are linked via one disulfide bond, and glycosylation of the γ sequence is proposed (4) (Fig. 5B). In this study, we analyzed the impact of successive mutations of these N-glycosylation recognition sites (Asn→Gln) on K1 toxicity and the intrinsic immunity mechanism. In contrast to an earlier study reporting a complete stop in toxin secretion after the application of tunicamycin (28), the substitution of the glycosylation sites had no impact on the toxin’s activity. By blocking the first step of N-glycosylation, tunicamycin induces ER stress via the accumulation of misfolded proteins, initiating the cellular unfolded protein response (29). Thus, the observed decrease in K1 secretion could be a consequence of a more general reduction in protein translation to restore protein homeostasis (30). Additionally, the peptidases Kex2p and Kex1p crucial for toxin maturation are heavily glycosylated proteins, and significant misfolding of these enzymes would lead to a similar phenotype that can be observed for Δkex2 deletion mutants (31, 32). Although glycosylation of the K1 protoxin has been verified via Western blotting and endoglycosidase H treatment, we propose that this posttranslational modification has no impact on the general K1 toxicity and might be just facilitating its processing (28) (Fig. 5B).

In addition to the chaperone-like function, the γ subunit has also been shown to be crucial for the formation of immunity (19). We analyzed a possible effect of this sequence on the secretion of biologically active toxin as well as the establishment of functional immunity after substitution with the corresponding subunit of K28. Although the sequences of both killer toxins show no sequence similarities, complete mediation of intrinsic immunity was observed for the respective transformants. Therefore, it could be hypothesized that only the physicochemical properties of the C-terminal elongation of α are important for the immunity mechanism independent from the exact amino acid sequence. However, yeast expressing this construct were not able to secrete a biologically active toxin, which was also reported for the analogous exchange in the K28 killer toxin in a previous study and is likely based on the distinct structural alteration of the killer toxins (14). To further examine the role of γ in K1 biology, we impaired the intramolecular Kex2p cleavage site. Although no reduction in toxicity was detected, a minor impairment in the formation of immunity was observed when K1 toxin was added externally. This disruption in the immunity mechanism was even more evident after coexpression of the mutated precursor toxin with different lethal constructs, indicating a significant role of Kex2p-dependent processing of the γ subunit as soon as free α molecules are present in the Golgi. Therefore, we analyzed αγ derivatives consisting of either the complete γ sequence or a truncated version of 39 amino acids resembling the subunit after intramolecular Kex2p cleavage. After intracellular expres-
TABLE 1 Prims used to generate K1 toxin derivatives

| Primer       | 5′→3′ sequence |
|--------------|----------------|
| S′ K1-pptox  | ctc gag gaa ttc ATG ACG AAG CCA CAA GTA TTA GTT AGA |
| S′ K28-pre   | ctc gag gaa ttc ATG ATG AGC GTT TCC TCA TTA TTT AAC A |
| S′ MFA-pre   | ctc gag gaa ttc ATG AGA TTT CTC TCA ATT TTT ACT GCA T |
| S′ K1-α      | ctc gag gaa ttc ATG GAA GCG CCG TGG TAT GAC AAG ATC TG |
| S′ K1-pptox  | aag ctc agt gggcgccgt CTG GTG GCC TGT GTC |
| S′ K1-α      | aag ctc gac ctc aag aag ctc TTA AGC AAG GCC ATT AGG ATC TGC |
| S′ K1-oR     | aag ctc gac ctc aag ctc TTA AGC AAG GCC ATT AGG AT |
| S′ K1-Pr     | aag ctc gac aag ctc TTA ACG ACG ACG ACG ACG ACG ACG ACG ACG ATT AGG AT |
| S′ K1-γ      | aag ctc gac aag ctc TTA AGC CIT GGC CAC TGC TGC TGT AAT G |
| S′ K1-γ(39)  | aag ctc gac aag ctc TTA GAC ATA TTG TGA TGC GTT ACG TGG GAG TAT ACT AAC |

*Restriction sites are illustrated as lowercase letters, and start and stop codons are underlined.

The results of this study not only support previous findings showing the ability of the first 31 amino acids of γ subunit's N terminus to confer full immunity but also highlight the importance of Kex2p-dependent processing and cleavage of γ (19).

In summary, we were able to strengthen and expand the current model of K1 toxin processing within the secretory pathway of the host cell. Based on the phenotypes of point-mutated K1 derivatives with altered Kex2p recognition sites in different toxin subunits, we postulate a model of K1 toxin maturation based on inactivation of the toxic α subunit by the proregion and the γ subunit. We suggest a successive proteolytical removal of the different protoxin regions in late Golgi compartments, thereby protecting the toxin-producing cell (Fig. 5C). The mature toxin heterodimer is further transported to the plasma membrane, where it is eventually secreted into the extracellular environment. Our data link different findings of previously conducted studies and provide valuable basics for future experiments. Moreover, we were able to describe a critical role of the N-terminal proregion in the maturation process for the first time. Future experiments could focus further on the ability of different N-terminal peptide sequences to inactivate the toxic K1-α subunit. For example, the chimeric K1 to K28 derivatives described in this study could be further analyzed by altering the Kex2p cleavage site of the K28 preregion. This could clarify if the observed phenotype is based on steric inhibition only or if a specific sequence-dependent mechanism is involved.

MATERIALS AND METHODS

**Strains, plasmids, and DNA manipulation.** Escherichia coli strain TOP10F′ (F′ [lacIq Tn10 (Tet)]) mcrA Δ(mr-hsdRMS-mccB8) F′lacZΔM15 lacX74 recA1 araD139 Δ(ara-leu)7697 galU galK rpsL (Strr) endA1 (Invitrogen) was used for cloning and amplification of all constructs. Cells were grown at 37°C in LB medium (1% tryptone, 0.5% yeast extract, and 0.5% sodium chloride) supplemented with 100 μg/ml of ampicillin when necessary. All K1 derivatives were generated by PCR and cloned into pYES2.1/V5-HIS-TOPO vector (Thermo Scientific) as described before (15) using the listed primers (Table 1); subcloning was conducted into the yeast expression vectors pYX242 and pRS316. The K1-sensitive *Saccharomyces cerevisiae* strain BY4742 (MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0) was obtained from DharmaconGE. K1 toxin was produced by *S. cerevisiae* strain T158c (MATα his4C-864). Cells were grown at 30°C in standard growth medium (1% yeast extract, 2% peptone, 2% glucose). Toxin production and concentration were determined as described before (33).

**Yeast transformation and selection.** For *in vivo* expression of K1 derivatives, *Saccharomyces cerevisiae* strain BY4742 was transformed by the standard lithium acetate method (34) and cultivated using appropriate selective media.

**Characterization of suicidal phenotype.** The lethal effect of intracellular expressed K1 derivatives was analyzed by performing serial dilution assays. Colonies of the respective transformants were inoculated in standard synthetic medium containing 2% glucose. After incubation for 16 h at 30°C, the cell number was determined, and 10⁴ cells were harvested. Cells were washed twice in synthetic medium containing 2% raffinose to eliminate remaining glucose. Subsequently, logarithmic dilutions were performed, and 10¹ to 10⁶ cells were spotted onto uracil (ura) dropout (d/o) and ura/leucine (leu) d/o (cotransformation) agar plates, respectively, containing either glucose (control) or galactose (inducing conditions). Plates were incubated for 3 days at 30°C, and cellular growth was documented.

**Analysis of toxin activity and mediation of immunity.** Biological activity of secreted K1 toxin was checked via MBA diffusion assay. Therefore, 10⁶ cells of the sensitive strain BY4724 were embedded into MBA agar (synthetic complete [sc] galactose, pH 4.7), and 10⁴ cells of the respective transformant were
spotted onto the plate. The mediation of functional immunity was analyzed by embedding 10⁶ cells of each transformant into MBAA agar (uracil galactose, pH 4.7), and applying 1,000 arbitrary units (AU) of K1 killer toxin. Toxin activity, as well as the formation of immunity, was documented after incubation of the plates for 3 days at 20°C (see Fig. S1 in the supplemental material).

SUPPLEMENTAL MATERIAL
Supplemental material is available online only.

FIG S1, TIF file, 0.2 MB.
FIG S2, TIF file, 0.5 MB.
FIG S3, TIF file, 0.1 MB.

ACKNOWLEDGMENT
S.G. and F.B. designed the experimental outline; S.G. performed the experiments; S.G., M.J.S., and F.B. analyzed the data; S.G. and F.B. wrote the paper.

We declare no conflict of interest.

REFERENCES
1. Wickner RB, Fujimura T, Esteban R. 2013. Viruses and prions of Saccharomyces cerevisiae. Adv Virus Res 86:1–36. https://doi.org/10.1016/B978-0-12-394351-6.00001-5.
2. Icho T, Wickner RB. 1989. The double-stranded RNA genome of yeast virus L-A encodes its own putative RNA polymerase by fusing two open reading frames. J Biol Chem 264:6716–6723.
3. Schmitt MJ, Breinig F. 2006. Yeast viral killer toxins: lethality and self-protection. Nat Rev Microbiol 4:212–221. https://doi.org/10.1038/nrmicro1347.
4. Gier S, Lermen M, Schmitt MJ, Breinig F. 2019. Substitution of cysteines in the yeast viral killer toxin K1 precursor reveals novel insights in heterodimer formation and immunity. Sci Rep 9:13127. https://doi.org/10.1038/s41598-019-49621-z.
5. Schmitt MJ, Breinig F. 2002. The viral killer system in yeast: from molecular biology to application. FEMS Microbiol Rev 26:257–276. https://doi.org/10.10111/j.1574-6976.2002.tb00614.x.
6. Hutchins K, Bussey H. 1983. Cell wall receptor for yeast killer toxin: involvement of (1 leads to 6)-beta-D-glucan. J Bacteriol 154:161–169. https://doi.org/10.1128/jb.154.1.161-169.1983.
7. Schmitt M, Radlfer F. 1987. Mannoprotein of the yeast cell wall as primary receptor for the killer toxin of Saccharomyces cerevisiae strain 28. J Gen Microbiol 133:3341–3347.
8. Esfeld K, Riffer F, Mentrjes G, Schmitt MJ. 2000. Endocytotic uptake and retrograde transport of a virally encoded killer toxin in yeast. Mol Microbiol 37:926–940. https://doi.org/10.1046j.1365-2958.2000.02063.x.
9. Becker B, Blum A, Gielfelmann E, Dausend J, Rettig J, Breinig F, Schmitt MJ. 2016. H/KDEL receptors mediate host cell intoxication by a viral A/B toxin in yeast. Sci Rep 6:31105. https://doi.org/10.1038/srep31105.
10. Breinig F, Riffer F, Schmitt MJ. 2002. KRE1p, the plasma membrane receptor for the yeast K1 viral toxin. Cell 108:395–405. https://doi.org/10.1016/S0092-8674(02)00634-7.
11. Breinig F, Schleinkofer K, Schmitt MJ. 2004. Yeast KRE1p is GPI-anchored and involved in both cell wall assembly and architecture. Microbiology 150:3209–3218. https://doi.org/10.1099/mic.0.27175-0.
12. Martinez B, Zhu H, Kubalski A, Zhou XL, Culbertson M, Bussey H, Kong C. 1990. Yeast K1 killer toxin forms ion channels in sensitive yeast spheroplasts and in artificial liposomes. Proc Natl Acad Sci U S A 87:6228–6232. https://doi.org/10.1073/pnas.87.16.6228.
13. de la Pen a P, Barros F, Gascon S, Ramos S, Lazo PS. 1980. Primary effects of yeast killer toxin. Biochim Biophys Acta 623:544–550. https://doi.org/10.1016/0005-2716(80)90139-0.
14. Breinig F, Sendzik T, Esfeld K, Schmitt MJ. 2006. Dissecting toxin immunity in virus-infected killer yeast uncovers an intrinsic strategy of self-protection. Proc Natl Acad Sci U S A 103:3810–3815. https://doi.org/10.1073/pnas.0510070103.
15. Gier S, Schmitt MJ, Breinig F. 2017. Expression of K1 toxin derivatives in Saccharomyces cerevisiae mimics treatment with exogenous toxin and provides a useful tool for elucidating K1 mechanisms of action and immunity. Toxins (Basel) 9:E345. https://doi.org/10.3390/toxins9110345.
16. Valis K, Masek T, Novotna D, Pospisek M, Janderova B. 2006. Immunity to killer toxin K1 is connected with the Golgi-to-vacuole protein degradation pathway. Folia Microbiol (Praha) 51:196–202. https://doi.org/10.1073/bf02932122.
17. Sturley S, Elliott Q, LeVitre J, Tipper DJ, Bostian KA. 1986. Mapping of functional domains within the Saccharomyces cerevisiae type 1 killer preprotoxin. EMBO J 5:3381–3389. https://doi.org/10.1002/1070-1879.1986.tb00654.x.
18. Tepper DJ, Breinig MJ. 1991. Yeast dsRNA viruses: replication and killer phenotypes. Mol Microbiol 5:2331–2338. https://doi.org/10.1111/j.1365-2958.1991.tb02078.x.
19. Zhu YS, Kane J, Zhang XY, Zhang M, Tipper DJ. 1993. Role of the gamma component present in precursor toxin of expression in the yeast K1 killer phenotype. Yeast 9:251–266. https://doi.org/10.1002/yea.32009305.
20. Bostian KA, Elliott Q, Bussey H, Bunn V, Smith A, Tipper DJ. 1984. Sequence of the preprotoxin dsRNA gene of type I killer yeast: multiple processing events produce a two-component toxin. Cell 36:741–751. https://doi.org/10.1016/0006-291x(84)90354-4.
21. Riffer F, Esfeld K, Breinig F, Schmitt MJ. 2002. Mutational analysis of K28 preprotoxin processing in the yeast Saccharomyces cerevisiae. Microbiol 148:1317–1328. https://doi.org/10.1046j.1365-287-1984-1313-5.
22. Hegde RS, Bernstein HD. 2006. The surprising complexity of signal sequences. Trends Biochem Sci 31:563–571. https://doi.org/10.1016/j.tibs.2006.08.004.
23. Jungnickel B, Rapoport TA. 1995. A posttargeting signal sequence recognition event in the endoplasmic reticulum membrane. Cell 82:261–270. https://doi.org/10.1016/0092-8674(95)90313-5.
24. Boone C, Bussey H, Greene D, Thomas DY, Vernet T. 1986. Yeast killer toxin: site-directed mutations implicate the precursor protein as the immunity component. Cell 46:105–113. https://doi.org/10.1002/0092-8674(86)09086-4.
25. Hansen W, Garcia PD, Walter P. 1986. In vitro protein translocation across the yeast endoplasmic reticulum: ATP-dependent posttranslational translocation of the prepro-alpha-factor. Cell 45:397–406. https://doi.org/10.1016/S0092-8674(86)30025-9.
26. Zhu YS, Zhang XY, Cartwright CP, Tipper DJ. 1992. Kex2-dependent processing of yeast K1 killer preprotoxin includes cleavage at ProArg-44. Mol Microbiol 6:511–520. https://doi.org/10.1111/j.1365-2958.1992.tb01496.x.
27. Bevan A, Brenner C, Fuller RS. 1998. Quantitative assessment of enzyme specificity in vivo: P2 recognition by Kex2 protease defined in a genetic system. Proc Natl Acad Sci U S A 95:10384–10389. https://doi.org/10.1073/pnas.95.18.10384.
28. Bussey H, Saville D, Greene D, Tipper DJ, Bostian KA. 1983. Secretion of Saccharomyces cerevisiae killer toxin: processing of the glycosylated precursor. Mol Cell Biol 3:1362–1370. https://doi.org/10.1128/mcb.3.8.1362.
29. Torres-Quiroz F, García-Márquez S, Coria R, Rangel-Gil F, Prieto JA. 2010. The activity of yeast Hog1 MAPK is required during endoplasmic reticulum stress induced by tunicamycin exposure. J Biol Chem 285:20088–20096. https://doi.org/10.1074/jbc.M110.063578.
30. Wu H, Ng BS, Thibault G. 2014. Endoplasmic reticulum stress response in yeast and humans. Biosci Rep 34:e00118. https://doi.org/10.1042/BSR2014005.
31. Schmitt MJ. 1995. Cloning and expression of a cDNA copy of the viral K28 killer toxin gene in yeast. Mol Gen Genet 246:236–246. https://doi.org/10.1007/bf00294687.
32. Schmitt MJ, Tipper DJ. 1995. Sequence of the M28 dsRNA: preprotoxin is processed to an alpha/beta heterodimeric protein toxin. Virology 213: 341–351. https://doi.org/10.1006/viro.1995.0007.
33. Gier S, Simon M, Nordstrom K, Khalifa S, Schulz MH, Schmitt MJ, Breinig F. 2019. Transcriptome kinetics of Saccharomyces cerevisiae in response to viral killer toxin K1. Front Microbiol 10:1102. https://doi.org/10.3389/fmicb.2019.01102.
34. Ito H, Fukuda Y, Murata K, Kimura A. 1983. Transformation of intact yeast cells treated with alkali cations. J Bacteriol 153:163–168. https://doi.org/10.1128/JB.153.1.163-168.1983.
35. Tipper DJ, Bostian KA. 1984. Double-stranded ribonucleic acid killer systems in yeasts. Microbiol Rev 48:125–156. https://doi.org/10.1128/MMBR.48.2.125-156.1984.